An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo

Hybridoma

Volumn 17, Issue 2, 1998, Pages 185-190

  Asano, Makoto ^a   Yukita, Ayako ^a   Matsumoto, Tomoe ^a   Hanatani, Mitsuya ^a   Suzuki, Hideo ^a  

^a Toagosei Co   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; DRUG POTENCY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GROWTH INHIBITION; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RNA SPLICING; TUMOR XENOGRAFT;

ANIMALIA; MUS MUSCULUS;

EID: 0031805836     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1998.17.185     Document Type: Article

References (26)

1. Folkman J: Tumor angiogenesis. Adv Cancer Res 1985;43: 175-203.
2. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
3. Folkman J, and Klagsbrun M: Angiogenic factors. Science 1987;235:442-447.
4. Klagsbrun M, and D'Amore PA: Regulators of angiogenesis. Ann Rev Physiol 1991;53:217-239.
5. Folkman J, and Shing Y: Angiogenesis. J Biol Chem 1992;267: 10931-10934.
6. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, and Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
7. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, and Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219: 983-985.
8. Plöuet J, Schilling J, and Gospodarowicz D: Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 1989;8:3801-3806.
9. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, and Leung DW: The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991;5:1806-1814.
10. Berger DP, Herbstritt L, Dengler WA, Marmé D, Mertelsman R, and Fiebig HH: Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. Annal Oncol 1995;6:817-825.
11. Kondo S, Asano M, and Suzuki H: Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem Biophys Res Commun 1993;194:1234-1241.
12. Kondo S, Asano M, Matsuo K, Ohmori I, and Suzuki H: Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patient. Biochim Biophys Acta 1994;1221:211-214.
13. Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, Tsuruta K, Taniguchi T, Okamoto A, Mori T, Yoshida M, Ikeda T, and Tominaga T: Concentration of vascular endothelial growth factor in the sera of normal control and cancer patients. Clin Cancer Res 1996;2:821-826.
14. Yeo KT, Wang HH, Nagy JA, Sioussat TM, Ledbetter SR, Hoogewerf AJ, Zhou Y, Masse EM, Senger DR, Dvorak HF, and Yeo TK: Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res 1993;53:2912-2918.
15. Senger DR, Perruzzi CA, Feder J, and Dvorak HF: A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986;46:5629-5632.
16. Zhang HT, Craft P, Scott PAE, Ziehe M, Weich HA, Harris AL, and Bicknell R: Enhancement of tumor growth and vascular density by transfection of vascular endothelial growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 1995; 87:213-219.
17. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (London) 1993;362:841-844.
18. Warren RS, Yuan H, Matil MR, Gillett NA, and Ferrara N: Regulation of vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental metastasis. J Clin Invest 1995;95:1789-1797.
19. Melnyk O, Shuman MA, and Kim KJ: Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res 1996;56:921-924.
20. 121). Hybridoma 1995;14:475-480.
21. 121. Cancer Res 1995;55: 5296-5301.
22. 121) produced by Saccharomyces cerevisiae promotes both angiogenesis and vascular permeability. Biochim Biophys Acta 1995;1243:195-202.
23. Ito Y, Iwamoto Y, Tanaka K, Okuyama K, and Sugioka Y: A quantitative assay using basement membrane extracts to study tumor angiogenesis in vivo. Int J Cancer 1996;67:148-152.
24. Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, and Ferrara N: Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. J Biol Chem 1996;271:5638-5646.
25. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, and Heldin CH: Different signal transduction properties of KDR and Fit-1, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988-26995.
26. Kim KJ, Li B, Houck K, Winer J, and Ferrara N: The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992;7:53-64.